Francoise A Marvel
Overview
Explore the profile of Francoise A Marvel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Javaid A, Baviriseaty S, Javaid R, Zirikly A, Kukreja H, Kim C, et al.
JACC Adv
. 2024 Oct;
3(9):101182.
PMID: 39372460
Background: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have surged in popularity in recent years, with discussions about their on-label and off-label use spilling into the public forum. No study has analyzed...
2.
Bhatla A, Ding J, Mhaimeed O, Spaulding E, Commodore-Mensah Y, Plante T, et al.
J Am Heart Assoc
. 2024 Aug;
13(17):e036475.
PMID: 39206726
Background: Prior studies have shown that cardiovascular disease (CVD) can be effectively managed through telehealth. However, there are little national data on the use of telehealth in people with CVD...
3.
Eidensohn Y, Bhatla A, Ding J, Blumenthal R, Martin S, Marvel F
Am J Prev Cardiol
. 2024 Jul;
19:100686.
PMID: 39070024
Objective: Elevated lipoprotein(a) [Lp(a)] is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease (ASCVD). We evaluated the frequency of testing for elevated Lp(a) and subsequent management at the...
4.
Johnson T, Chilazi M, Isakadze N, Desai K, Spaulding E, Goyal A, et al.
JACC Adv
. 2024 Jun;
2(7):100587.
PMID: 38939478
No abstract available.
5.
6.
Marvel F, Grant J, Martin S
Circ Cardiovasc Qual Outcomes
. 2024 Apr;
17(5):e010884.
PMID: 38634283
No abstract available.
7.
Mhaimeed O, Burney Z, Schott S, Kohli P, Marvel F, Martin S
Am J Prev Cardiol
. 2024 Apr;
18:100649.
PMID: 38576462
Cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cardiovascular disease (ASCVD) risk. An armamentarium of therapies to achieve robust and sustained reduction in LDL-C can...
8.
Brownstein A, Derenbecker R, Gao Y, Ding J, Varghese B, Isakadze N, et al.
Am Heart J Plus
. 2024 Apr;
13:100082.
PMID: 38560081
Objective: The 2018 AHA/ACC cholesterol guidelines recommend considering non-statin agents among very high-risk (VHR) patients with LDL-C ≥ 70 mg/dL after maximizing statin therapy. We aimed to evaluate the prevalence...
9.
Isakadze N, Kim C, Marvel F, Ding J, MacFarlane Z, Gao Y, et al.
J Am Heart Assoc
. 2024 Jan;
13(2):e030654.
PMID: 38226511
Background: Cardiac rehabilitation (CR) is an evidence-based, guideline-recommended intervention for patients recovering from a cardiac event, surgery or procedure that improves morbidity, mortality, and functional status. CR is traditionally provided...
10.
Bhatla A, Kim C, Nimbalkar M, Ng-Thow-Hing A, Isakadze N, Spaulding E, et al.
J Am Heart Assoc
. 2024 Jan;
13(2):e031621.
PMID: 38226509
No abstract available.